Structured Answers

1. Definition & Etiology

Acute Post-Streptococcal Glomerulonephritis (APSGN) is the most common form of acute GN in children — an immune complex-mediated disease following infection with nephritogenic strains of Group A β-hemolytic Streptococcus.

• •Agent: Nephritogenic strains of Group A β-hemolytic Streptococcus
• •Trigger: Pharyngitis (5-21 days, average 10 days) or skin infection/impetigo (3-6 weeks)
• •Age: Peak 2-12 years; more common in boys; rare <2 years
• •Pathophysiology: Streptococcal antigens → immune complex deposition (IgG + C3) in subepithelial locations forming "humps" on EM → complement activation → neutrophil influx → decreased GFR

2. Clinical Features

• •Classic Triad (Nephritic Syndrome): Hematuria (smoky/tea-colored, RBC casts pathognomonic), Edema (periorbital, pitting, sudden), Hypertension (salt-water retention)
• •Associated: Oliguria, mild proteinuria (<1 g/day), azotemia (fatigue, nausea, anorexia), fever, flank pain, hypertensive encephalopathy (headache, seizures, papilledema), CCF/heart failure (severe HTN + fluid overload)

2A. AGN vs Nephrotic Syndrome — Key Differentiator

The examiner repeatedly tests the ability to distinguish AGN from NS. This comparison table is high-yield.

3. Investigations

4. Management

• •General: Bed rest, salt and fluid restriction (to insensible + urine output). Daily monitoring: BP, weight, strict I/O chart.
• •Hypertension: First-line: Nifedipine (calcium channel blocker) oral. Emergency: IV Labetalol or Nitroprusside.
• •Hyperkalemia: Calcium gluconate → insulin + glucose → sodium bicarbonate. Dialysis if refractory.
• •Fluid overload: Furosemide 1-2 mg/kg IV.
• •Azotemia/AKI: Dialysis if refractory fluid overload, severe hyperkalemia, or uremic symptoms.
• •Strep eradication: Benzathine Penicillin G 600,000 U IM (<27 kg) or 1.2 million U IM (>27 kg) single dose. Alternative: Penicillin V 250 mg PO BD-TDS x 10 days (older children). If allergic: Erythromycin or Azithromycin.
• •Negative points: NO corticosteroids/immunosuppressants in APSGN. ACE inhibitors are NOT first-line for acute HTN (can worsen hyperkalemia + AKI). Diuretics are NOT first-line for HTN (used only for fluid overload).

5. Complications & Prognosis

• •AKI — reversible; dialysis rarely needed
• •Hypertensive encephalopathy — seizures, papilledema
• •CCF / Heart failure — due to severe HTN + fluid overload
• •Acute pulmonary edema — fluid overload
• •CKD — rare (<1%); consider if crescents on biopsy
• •Prognosis: Excellent; >95% complete recovery. Gross hematuria resolves in 5-10 days. Microscopic hematuria may persist months-years. C3 normalizes by 6-8 weeks. If C3 remains low >8-12 weeks, suspect MPGN.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Confusing AGN with NS — remember: AGN has hematuria + HTN + low C3; NS has massive proteinuria + hypoalbuminemia + no HTN
• •Trap 2: Using ACE inhibitors as first-line for AGN HTN — NO; first-line is Nifedipine (CCB). ACEi can worsen hyperkalemia and AKI.
• •Trap 3: Using diuretics for HTN — NO; diuretics are only for fluid overload, not HTN control.
• •Trap 4: Prescribing steroids for PSGN — NO; therapy is supportive only.
• •Trap 5: Forgetting pediatric penicillin dosing — weight-based: 600K U (<27 kg) or 1.2M U (>27 kg) IM.
• •Trap 6: Normal C3 + normal C4 + hematuria → think IgA nephropathy (not PSGN).
• •High-yield: PSGN can develop even after antibiotic treatment of strep infection.

1. Definition & Classification

Nephrotic Syndrome (NS) is defined by nephrotic-range proteinuria (>50 mg/kg/day or urine protein/creatinine ratio >2.0 mg/mg), hypoalbuminemia (<2.5 g/dL), hyperlipidemia, and edema.

2. Clinical Features

• •Edema - periorbital (worse in morning), dependent (legs by evening), ascites, pleural effusion, scrotal edema
• •Frothy urine - due to massive proteinuria
• •Weight gain - fluid retention
• •Anorexia, lethargy, diarrhea - gut edema
• •Hypovolemia signs - cold peripheries, tachycardia, hypotension (despite edema!)
• •Infections - loss of IgG and complement factors in urine
• •Thrombosis - loss of antithrombin III; renal vein thrombosis most common

3. Investigations

4. Management

• •General: Bed rest during edema phase. Normal protein intake (do NOT restrict). Salt restriction during edema. Daily weight, BP, urine protein dipstick, I/O chart.
• •Edema: Loop diuretics (Furosemide) for severe edema; monitor for hypovolemia.
• •Steroid Regimen (First Episode — ISKD Protocol): Prednisolone 2 mg/kg/day (max 60 mg/day) x 6 weeks → 1.5 mg/kg alternate days x 6 weeks → taper. Total 12 weeks for responders (best long-term results).
• •Hypovolemia/Shock: 25% albumin 0.5-1.0 g/kg IV over 1-2 hours + IV loop diuretic.
• •Infection (SBP/cellulitis): Ceftriaxone. Vaccinate with Pneumococcal + Varicella. Organisms: S. pneumoniae, E. coli, Klebsiella.
• •Thrombosis: LMWH, then warfarin.
• •Adjunctive: ACE inhibitors (Enalapril) for persistent HTN/proteinuria. Spironolactone (K+-sparing diuretic) may be used cautiously.
• •Steroid-Sparing Agents: Cyclophosphamide 2 mg/kg/day PO x 8-12 weeks (cumulative 168 mg/kg). Cyclosporine 3-5 mg/kg/day. Tacrolimus 0.1 mg/kg/day. MMF 600-1200 mg/m²/day. Rituximab for severe cases.

5. Complications & Prognosis

• •Infections: Spontaneous bacterial peritonitis (S. pneumoniae, E. coli, Klebsiella), cellulitis, sepsis. Loss of IgG, Factor B, properdin.
• •Thromboembolism: Renal vein thrombosis (most common). Loss of antithrombin III, proteins C & S.
• •Hypovolemia/AKI: Acute pre-renal failure. Hypotension, cold peripheries.
• •Other: Growth retardation (chronic steroids), cataracts, osteoporosis, hypothyroidism (loss of TBG), hypocalcemia/tetany (loss of vitamin D-binding protein).
• •Prognosis: MCD: Excellent; 80% achieve remission with steroids; relapses decrease with age. FSGS: ~35% respond to steroids; 50% progress to ESRD within 10 years.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Confusing NS with AGN — NS has NO hematuria, NO HTN, normal C3; AGN has all three.
• •Trap 2: Wrong steroid dose — must specify 2 mg/kg/day (MAX 60 mg/day); not 1 mg/kg.
• •Trap 3: Wrong steroid duration — total 12 weeks for responders, not 6 weeks only.
• •Trap 4: Using ACE inhibitors for acute HTN in NS — use CCBs (Amlodipine) first; ACEi is for persistent HTN/proteinuria.
• •Trap 5: Forgetting salt restriction — as important as steroids for edema control.
• •Trap 6: Protein restriction — NO; maintain normal protein intake.
• •High-yield: S. pneumoniae is the #1 organism for SBP in NS — vaccinate!
• •High-yield: Biopsy BEFORE steroids if low C3, >8 years, or atypical features.

1. Definition

Rickets is defined as decreased or defective bone mineralization in growing children; osteomalacia is the adult equivalent.

2. Biochemical Changes

Low dietary Vit D / Sunlight → Low 25-OH Vit D (<8 ng/mL suggests deficiency) → Low intestinal Ca absorption → Hypocalcemia → High PTH secretion (secondary hyperparathyroidism) → Renal phosphate wasting + Bone resorption → Hypophosphatemia → Low Ca x PO4 product (<30 mg²/dL²) → Defective mineralization of osteoid → Rickets

3. Clinical Features

• •Head & Chest: Craniotabes (ping-pong ball sensation, 3-6 months), delayed fontanelle closure (>18 months), rachitic rosary (costochondral beading, ribs 5-8), Harrison's sulcus, pectus carinatum/excavatum
• •Extremities & Spine: Wrist widening, ankle widening, bow legs (genu varum, <3 years), knock knees (genu valgum, >3 years), delayed teething (>12 months), kyphosis/scoliosis, bone pain/tenderness
• •Systemic: Delayed motor milestones (sitting, walking), proximal muscle weakness/myopathy, failure to thrive
• •Emergency: Hypocalcemic seizures/tetany (severe rickets) — treat with IV calcium gluconate 1-2 mL/kg of 10% solution slowly over 10 minutes with cardiac monitoring

4. Radiological Findings (X-ray Wrist - AP View)

• •Cupping - concavity of metaphysis (saucerization)
• •Fraying - irregular, brush-like appearance of metaphyseal margins
• •Splaying - widening of growth plate (>2 mm)
• •Reduced bone density - coarsened trabecular pattern
• •Greenstick fractures

5. Management

• •Emergency (hypocalcemic seizures/tetany): IV calcium gluconate 1-2 mL/kg of 10% solution given slowly over 10 minutes with ECG monitoring for bradycardia.
• •Monitoring: Clinical improvement in 2-4 weeks; radiological healing in 3-6 months. Monitor serum Ca, PO4, ALP at 4, 8, 12 weeks.
• •Surgical: Corrective osteotomy for severe deformities (after healing of rickets).
• •Prevention: Breastfed infants: 400 IU/day Vit D3 from first few days. Formula-fed: supplement if <1 L/day. Pregnant/lactating mothers: 600-1000 IU/day. Sun exposure: 15-30 min/day. High-risk: dark skin, limited sun, malabsorption.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Confusing rickets with scurvy — scurvy has white line of Fraenkel on X-ray and bleeding gums; rickets has cupping/fraying/splaying.
• •Trap 2: Normal calcium in early rickets — PTH rises FIRST to maintain calcium; do not expect hypocalcemia initially.
• •Trap 3: Vit D dependent Type I — normal 25(OH)D but low 1,25(OH)2D; differs from nutritional deficiency.
• •Trap 4: XLH — normal calcium, normal 25(OH)D, low phosphate only; treat with phosphate + calcitriol (NOT calcium).
• •Trap 5: Forgetting elemental calcium supplementation alongside vitamin D.
• •High-yield: Rachitic rosary is most prominent at ribs 5-8.
• •High-yield: 25(OH)D <8 ng/mL suggests nutritional deficiency (not <20).
• •High-yield: Radiological healing takes 3-6 months — slower than clinical improvement.

1. Definition & Etiology

Congenital Hypothyroidism (CH) is thyroid hormone deficiency present at birth. Most common preventable cause of intellectual disability. Incidence: 1:2500-1:4000 live births.

2. Clinical Features

CRITICAL: The examiner tests neonatal features, NOT childhood features. Do NOT mention short stature or intellectual disability — those develop if untreated.

• •Neonatal Period (First 2-4 Weeks) — THESE ARE THE EXAM ANSWERS: Prolonged physiological jaundice (>7 days) — unconjugated, hypotonia, lethargy, poor feeding, constipation, hypothermia (cold, mottled skin), large anterior + posterior fontanelle, bradycardia, respiratory distress (myxedema of vocal cords), edema (periorbital, peripheral), hoarse cry, macroglossia, umbilical hernia
• •Infantile Period (2-3 Months Onwards): Coarse facies (flat nasal bridge, puffy eyes, macroglossia), umbilical hernia, goiter (in dyshormonogenesis), developmental delay, hoarse cry, dry skin, sparse hair, short stature, anemia (macrocytic)

3. Newborn Screening

• •All newborns screened at day 3-5 of life (before discharge, optimally 48-72h after birth to avoid physiological TSH surge)
• •Primary screening: TSH (most common) or T4
• •Abnormal: TSH >20-40 mIU/L; T4 <10 microg/dL
• •Confirmatory: Serum TSH, free T4, total T4
• •If TSH high + T4 low: Primary hypothyroidism
• •If TSH low/normal + T4 low: Central hypothyroidism - do MRI pituitary

3A. Neonatal vs Childhood Features — Examiner Trap

4. Management

• •Levothyroxine (L-thyroxine): 10-15 microg/kg/day PO started immediately after confirmation
• •Start treatment within 2 weeks of life for normal neurodevelopmental outcome
• •Crush tablet, mix with breast milk/formula. Do NOT give with soy/iron/calcium (reduces absorption)
• •Monitoring: TSH and free T4 every 1-2 months in first 6 months; then every 3 months until age 3; then every 6-12 months
• •Target: TSH 0.5-2.0 mIU/L; free T4 in upper normal range
• •Prognosis: Excellent if treatment starts within 2 weeks; IQ normal

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Listing childhood features (short stature, intellectual disability) instead of neonatal features — examiner wants neonatal features specifically.
• •Trap 2: Forgetting unconjugated hyperbilirubinemia — not conjugated.
• •Trap 3: Wrong screening timing — day 3-5, not immediately at birth (physiological TSH surge).
• •Trap 4: Missing central hypothyroidism — low/normal TSH + low T4 = MRI pituitary.
• •Trap 5: Giving levothyroxine with soy/iron/calcium — reduces absorption.
• •High-yield: Most common preventable cause of intellectual disability — start before 2 weeks.
• •High-yield: TSH screening cutoff: >20-40 mIU/L.

1. Differential Diagnosis of Acute Scrotum

2. Clinical Features of Testicular Torsion

• •Sudden severe unilateral scrotal pain (often wakes child from sleep)
• •Nausea and vomiting (due to severe pain)
• •High-riding testis (horizontal lie - "bell-clapper deformity")
• •Absent cremasteric reflex (most sensitive sign)
• •Scrotal swelling, erythema, tenderness
• •No relief with elevation (vs epididymitis where elevation helps - Prehn's sign)

3. Investigations

• •Color Doppler USG - test of choice; shows absent or decreased blood flow to testis (sensitivity 90-100%)
• •Radionuclide scan - rarely used now; "cold spot" in torsion
• •Urine analysis - normal (vs pyuria in infection)
• •Do NOT delay surgery for imaging if clinical suspicion is high

4. Emergency Management

• •Immediate surgical exploration - do not wait for imaging if strongly suspected
• •Manual detorsion may be attempted as a temporizing measure ("open the book" - rotate testis laterally 180 degrees x 2)
• •Scrotal exploration: Detorsion, assess viability (warm packs), bilateral orchidopexy (fix both testes to prevent future torsion)
• •Salvage rate: >90% if surgery within 6 hours; <10% if >24 hours

1. Classification of Hematuria

• •Glomerular Hematuria: Color: Cola/tea/smoky (brown). RBCs: Dysmorphic, fragmented (acanthocytes). Casts: RBC casts pathognomonic. Proteinuria: Present (often >+++). Clots: Absent. Associated: Edema, hypertension, decreased GFR.
• •Non-Glomerular Hematuria: Color: Fresh red/pink. RBCs: Isomorphic (normal shape). Casts: Absent. Proteinuria: Minimal or absent. Clots: May be present. Associated: Dysuria, flank pain, trauma history.

2. Differential Diagnosis

• •Glomerular causes: AGN/PSGN, IgA Nephropathy (Synpharyngitic hematuria), HSP/IgA vasculitis, Alport Syndrome (X-linked, hearing loss), MPGN, Thin Basement Membrane Disease
• •Non-glomerular causes: UTI, Urolithiasis, Trauma, Hypercalciuria (#1 cause of isolated hematuria), Coagulopathy, Sickle Cell Trait/Disease, Wilms Tumor, PUV/UPJ obstruction

3. Key Investigations

1. Definition

• •Operational threshold: Plasma glucose <40 mg/dL in the first 24 hours; <45 mg/dL after 24 hours
• •Neuroglycopenic threshold: <30 mg/dL - risk of permanent brain injury

2. Risk Factors

• •Increased Utilization / Decreased Stores: Preterm/SGA/IUGR (decreased glycogen stores), perinatal asphyxia, hypothermia, sepsis, polycythemia
• •Hyperinsulinism / Endocrine: Infant of Diabetic Mother (IDM), LGA, Beckwith-Wiedemann syndrome, transfusion/exchange, pituitary/adrenal insufficiency, inborn errors of metabolism

3. Clinical Features

Asymptomatic hypoglycemia is common - detected only on screening

4. Management

• •Screening: All at-risk neonates at 2, 6, 12, 24, 36, 48 hours
• •Asymptomatic (glucose 25-40): Feed immediately; recheck in 30 min
• •Symptomatic or <25 mg/dL: IV D10 2 mL/kg bolus then D10 maintenance 80-100 mL/kg/day
• •Goal: Maintain glucose >45-50 mg/dL
• •If persistent: Increase GIR to 8-12 mg/kg/min; add glucagon 0.03 mg/kg IV or hydrocortisone 5 mg/kg/day
• •Refractory: Evaluate for hyperinsulinism then Diazoxide / Octreotide / Surgery

1. Definition

Intussusception is the telescoping (invagination) of a proximal segment of bowel (intussusceptum) into the distal segment (intussuscipiens). It is the most common cause of intestinal obstruction in children aged 6-36 months.

• •Idiopathic (90%): Lymphoid hyperplasia of Peyer patches (post-viral)
• •Lead point (10%): Meckel diverticulum, polyp, lymphoma, duplication cyst, HSP

2. Clinical Features

• •Classic Triad: Severe episodic crying (colicky pain), vomiting (bilious if advanced), currant jelly stool (blood + mucus)
• •Other: Drawing up of legs toward abdomen during episodes, lethargy between episodes, sausage-shaped abdominal mass (right upper quadrant), empty right lower quadrant (Dance sign)

3. Investigations

• •USG Abdomen - test of choice; shows "target sign" or "doughnut sign" (concentric rings)
• •Abdominal X-ray - signs of obstruction (air-fluid levels), paucity of gas in RLQ, soft tissue mass
• •Contrast Enema - diagnostic and therapeutic; shows "coiled spring sign" or "meniscus sign"
• •Air Enema - preferred for reduction under fluoroscopy
• •Do NOT perform contrast enema if signs of perforation or peritonitis

4. Management

• •Non-operative (First Line): Air/contrast enema reduction under fluoroscopy. Success rate: 80-90%. Contraindications: Peritonitis, perforation, shock, failed enema reduction.
• •Operative: Manual reduction via laparotomy or laparoscopy. Resection if gangrenous bowel or lead point.
• •Pre-operative: IV fluids, NG tube decompression, antibiotics, correct electrolytes.

1. Definition & Pathophysiology

Portal Hypertension is a pathological increase in portal venous pressure (>10 mmHg or gradient >5 mmHg). It results from increased resistance to portal blood flow and/or increased portal blood flow.

• •Pre-hepatic: Portal vein thrombosis, congenital atresia/stenosis, compression by tumor/cyst
• •Hepatic (most common): Cirrhosis, congenital hepatic fibrosis, schistosomiasis
• •Post-hepatic: Budd-Chiari syndrome, constrictive pericarditis, veno-occlusive disease

2. Clinical Features

• •Splenomegaly - most common sign; hypersplenism (pancytopenia)
• •Ascites - fluid accumulation in peritoneal cavity
• •Caput medusae - dilated periumbilical veins
• •Hematemesis/Melena - from esophageal/gastric variceal bleeding (life-threatening)
• •Hepatic encephalopathy - confusion, asterixis, altered consciousness
• •Pruritus, jaundice, palmar erythema, spider angiomas - signs of chronic liver disease

3. Investigations

4. Management

• •Acute Variceal Bleeding: IV fluids, blood transfusion (Hb target 7-8 g/dL), antibiotics (Ceftriaxone - prevent SBP), vasoactive drugs (Octreotide/Terlipressin), endoscopic band ligation (EBL) or sclerotherapy. Balloon tamponade (Sengstaken-Blakemore) if refractory. TIPS if endoscopy fails.
• •Prevention of Rebleeding: Non-selective beta-blockers (Propranolol), repeated EBL until varices obliterated.
• •Primary Prophylaxis: Non-selective beta-blockers or EBL if high-risk varices.
• •Portosystemic Shunt Surgery: Devascularization procedures (Sugiura), shunt procedures (MESO-Rex bypass for portal vein thrombosis), liver transplantation (definitive for end-stage liver disease).
• •General: Low sodium diet, diuretics (Spironolactone + Furosemide) for ascites, lactulose/rifaximin for encephalopathy, nutritional support.

5. Complications

• •Variceal bleeding (life-threatening)
• •Hepatic encephalopathy
• •Ascites and spontaneous bacterial peritonitis (SBP)
• •Hepatorenal syndrome
• •Hepatopulmonary syndrome / portopulmonary hypertension

1. Definition & Pathophysiology

Hemolytic Uremic Syndrome (HUS) is a thrombotic microangiopathy characterized by the classic triad: hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). It is the most common cause of AKI in children.

• •Typical HUS (90%): Caused by Shiga toxin-producing E. coli (STEC) - O157:H7, O104:H4. Toxin binds to globotriaosylceramide (Gb3) receptors on glomerular endothelial cells → endothelial damage → platelet activation → microthrombi formation → microangiopathic hemolytic anemia + thrombocytopenia + AKI.
• •Atypical HUS (10%): Due to complement dysregulation (mutations in CFH, CFI, MCP, C3, CFHR, THBD) or secondary causes (pneumococcal infection, drugs, malignancy, autoimmune).

2. Clinical Features

• •Prodrome: Bloody diarrhea (hemorrhagic colitis) 5-10 days before HUS onset. Severe abdominal pain, vomiting.
• •Hematologic: Pallor, fatigue, petechiae, ecchymoses, mucosal bleeding (epistaxis, gingival).
• •Renal: Oliguria/anuria, edema, hypertension, hematuria, proteinuria.
• •Other: Fever, irritability, seizures (hypertensive encephalopathy), pancreatitis, cardiomyopathy, CNS involvement.

3. Investigations

4. Management

• •Supportive Care (Mainstay): Strict fluid and electrolyte management. Treat hyperkalemia, acidosis, hypertension. Blood transfusion for symptomatic anemia (Hb <6 g/dL or hemodynamic compromise). Platelet transfusion only for active bleeding or invasive procedures.
• •Nutrition: Early enteral nutrition. Parenteral nutrition if contraindicated.
• •Dialysis: Indicated for refractory fluid overload, severe hyperkalemia, severe metabolic acidosis, uremic symptoms, oliguria >24h. Peritoneal dialysis preferred in children.
• •Antibiotics: Generally AVOIDED in typical STEC-HUS (may increase Shiga toxin release). Use only for documented sepsis or pneumococcal HUS.
• •Eculizumab: Humanized anti-C5 monoclonal antibody. Indicated for atypical HUS. Extremely expensive. Vaccinate against meningococcus before starting.
• •Plasma Exchange: For severe aHUS or TTP-like presentation.
• •Other: No role for heparin, aspirin, or antiplatelet agents in typical HUS.

5. Prognosis

• •Typical HUS: Mortality 3-5%. Most children recover fully. 30% may have long-term sequelae (proteinuria, hypertension, CKD).
• •Atypical HUS: Poor prognosis without treatment. 50% mortality/ESRD in first year. Eculizumab has dramatically improved outcomes.
• •Poor prognostic factors: Atypical HUS, CNS involvement, prolonged anuria (>7 days), severe thrombocytopenia.

1. Definition & Classification

Biliary Atresia (BA) is a progressive, idiopathic, obliterative cholangiopathy involving the extrahepatic (and sometimes intrahepatic) bile ducts. It is the most common cause of neonatal cholestasis and the leading indication for liver transplantation in children.

• •Type I (10%): Obliteration of common bile duct only. Most favorable prognosis.
• •Type II (2%): Obliteration of common hepatic duct.
• •Type III (88%): Obliteration of entire extrahepatic biliary tree up to porta hepatis. Most common and most severe.
• •Associated anomalies (10-20%): Biliary atresia splenic malformation (BASM) syndrome - polysplenia, situs inversus, malrotation, cardiac defects, preduodenal portal vein.

2. Clinical Features

• •Jaundice: Progressive, conjugated hyperbilirubinemia. Persists beyond 14 days of life (physiological jaundice resolves by 2 weeks).
• •Acholic (pale/white) stools: Due to absence of bile reaching intestine. Most specific sign.
• •Dark urine: Conjugated bilirubin excreted in urine.
• •Hepatomegaly: Firm, enlarged liver. Splenomegaly in advanced disease.
• •Ascites, failure to thrive, bleeding tendency, pruritus - signs of end-stage liver disease.

3. Investigations

4. Management

• •Kasai Portoenterostomy (First Line): Excision of fibrotic biliary remnant + Roux-en-Y jejunal loop anastomosed to porta hepatis to restore bile drainage. Timing is critical: Best outcomes if performed <60 days of age. Success rate drops dramatically after 90 days.
• •Pre-operative: Vitamin K (correct coagulopathy), nutritional support (MCT-containing formula), choleretics (ursodeoxycholic acid), antibiotics.
• •Post-operative: Prednisolone (improve bile flow), prophylactic antibiotics (prevent cholangitis), ursodeoxycholic acid, fat-soluble vitamins (A, D, E, K).
• •Liver Transplantation: Definitive treatment for failed Kasai or end-stage liver disease. 80-90% survival at 5 years.
• •Cholangitis: Most common complication post-Kasai. Fever, increased jaundice, acholic stools. Treat with broad-spectrum IV antibiotics.

5. Prognosis

• •Kasai success (jaundice-free) in 50-60% if performed <60 days.
• •Native liver survival: 50% at 5 years, 30% at 10 years.
• •Overall survival with transplant: 80-90% at 5 years, 80% at 20 years.
• •Poor prognostic factors: Age >90 days at Kasai, Type III, BASM syndrome, post-operative cholangitis, portal hypertension.

1. Definition & Pathophysiology

Diabetic Ketoacidosis (DKA) is a life-threatening complication of Type 1 DM characterized by hyperglycemia (BG >200 mg/dL), metabolic acidosis (pH <7.30), and ketonemia/ketonuria.

• •Insulin deficiency → decreased glucose utilization → hyperglycemia → osmotic diuresis → dehydration + electrolyte losses.
• •Lipolysis → increased free fatty acids → hepatic ketogenesis (beta-hydroxybutyrate, acetoacetate) → metabolic acidosis.
• •Counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone) further worsen hyperglycemia and ketosis.

2. Clinical Features

• •Hyperglycemia symptoms: Polyuria, polydipsia, weight loss, dehydration (dry mucous membranes, poor skin turgor, tachycardia, hypotension)
• •Acidosis symptoms: Kussmaul breathing (deep, rapid, sighing respirations), acetone breath (fruity odor)
• •GI symptoms: Nausea, vomiting, abdominal pain (may mimic acute abdomen)
• •CNS symptoms: Altered consciousness, lethargy, confusion, coma (cerebral edema - most feared complication)

3. Management

• •Fluid Resuscitation: 0.9% NS 10-20 mL/kg over 1-2 hours (initial). Then 0.45-0.9% NS + dextrose. Replace deficit over 48 hours. Avoid overly rapid correction.
• •Insulin: Regular insulin 0.05-0.1 U/kg/hr IV infusion. Start AFTER 1-2 hours of fluid resuscitation. Do NOT bolus. Continue until acidosis resolves (pH >7.30, bicarbonate >18).
• •Potassium: Add 20-40 mEq/L once urine output confirmed and K+ <5.5 mEq/L. Hold insulin if K+ <3.3 mEq/L (risk of arrhythmia).
• •Bicarbonate: Generally AVOIDED. May consider if pH <6.9 with hemodynamic instability.
• •Phosphate: Replace if <1 mg/dL or cardiac dysfunction/hemolysis present.
• •Dextrose: Add D5 or D10 when BG drops to 200-250 mg/dL. Continue insulin to clear ketosis.

4. Monitoring & Complications

• •Monitoring: Blood glucose hourly, electrolytes and VBG every 2-4 hours, neuro checks hourly, fluid balance hourly, ECG monitoring.
• •Cerebral Edema (most feared): Headache, bradycardia, hypertension, altered consciousness, seizures, pupillary changes. Treat with mannitol 0.5-1 g/kg or 3% hypertonic saline 5-10 mL/kg. Reduce fluid rate, elevate head.
• •Hypoglycemia: Add dextrose to IV fluids.
• •Hypokalemia: Aggressive K+ replacement.
• •Resolution criteria: BG <200 mg/dL, pH >7.30, HCO3 >18 mEq/L, closed anion gap, ability to tolerate oral intake.